Is IBIO or BCYC more profitable?

iBio has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Bicycle Therapeutics -311.11% -33.22% -27.79%

Which has higher earnings & valuation, IBIO or IMRX?

iBio has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 173.88 -$18.38M -$0.58 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is IBIO or IMRX more profitable?

Immuneering's return on equity of -31.93% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Immuneering N/A -31.93% -29.92%

Do analysts prefer IBIO or TKNO?

iBio presently has a consensus price target of $5.00, suggesting a potential upside of 257.14%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than Alpha Teknova. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Alpha Teknova 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings and valuation, IBIO or TKNO?

Alpha Teknova has higher revenue and earnings than iBio. Alpha Teknova is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 173.88 -$18.38M -$0.58 N/A Alpha Teknova $40.52M 6.62 -$17.26M -$0.32 N/A

Is IBIO or TKNO more profitable?

iBio has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Alpha Teknova -41.07% -24.32% -16.34%

Is FATE or IBIO more profitable?

iBio has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. iBio's return on equity of -53.86% beat Fate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fate Therapeutics -2,056.79% -58.89% -39.39% iBio N/A -53.86% -46.48%

Which has better earnings and valuation, ALXO or IBIO?

iBio has higher revenue and earnings than ALX Oncology. iBio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A iBio $400K 173.88 -$18.38M -$0.58 N/A

Is ALXO or IBIO more profitable?

iBio's return on equity of -53.86% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% iBio N/A -53.86% -46.48%

iBio (IBIO) Competitors

$1.40 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 07/31/2026 07:34 PM Eastern

Compare

IBIO vs. BCYC, IMRX, TKNO, FATE, and ALXO

Should you buy iBio stock or one of its competitors? MarketBeat compares iBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iBio include Bicycle Therapeutics (BCYC), Immuneering (IMRX), Alpha Teknova (TKNO), Fate Therapeutics (FATE), and ALX Oncology (ALXO).

How does iBio compare to Bicycle Therapeutics?

iBio (NASDAQ:IBIO) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

iBio has higher earnings, but lower revenue than Bicycle Therapeutics. iBio is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	173.88	-$18.38M	-$0.58	N/A
Bicycle Therapeutics	$61.21M	4.40	-$218.96M	-$2.73	N/A

iBio has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

7.9% of iBio shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 257.14%. Bicycle Therapeutics has a consensus target price of $13.86, indicating a potential upside of 258.99%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Bicycle Therapeutics had 7 more articles in the media than iBio. MarketBeat recorded 7 mentions for Bicycle Therapeutics and 0 mentions for iBio. iBio's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.45 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Neutral
Bicycle Therapeutics	Neutral

iBio has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

Summary

Bicycle Therapeutics beats iBio on 10 of the 17 factors compared between the two stocks.

How does iBio compare to Immuneering?

iBio (NASDAQ:IBIO) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

iBio has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	173.88	-$18.38M	-$0.58	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

iBio has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

In the previous week, Immuneering's average media sentiment score of 0.51 beat iBio's score of 0.00 indicating that Immuneering is being referred to more favorably in the news media.

Company	Overall Sentiment
iBio	Neutral
Immuneering	Positive

7.9% of iBio shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 14.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immuneering's return on equity of -31.93% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Immuneering	N/A	-31.93%	-29.92%

iBio currently has a consensus target price of $5.00, indicating a potential upside of 257.14%. Immuneering has a consensus target price of $17.57, indicating a potential upside of 325.46%. Given Immuneering's higher probable upside, analysts clearly believe Immuneering is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

iBio and Immuneering tied by winning 7 of the 14 factors compared between the two stocks.

How does iBio compare to Alpha Teknova?

iBio (NASDAQ:IBIO) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

7.9% of iBio shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

iBio has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Alpha Teknova	-41.07%	-24.32%	-16.34%

iBio presently has a consensus price target of $5.00, suggesting a potential upside of 257.14%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Alpha Teknova has higher revenue and earnings than iBio. Alpha Teknova is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	173.88	-$18.38M	-$0.58	N/A
Alpha Teknova	$40.52M	6.62	-$17.26M	-$0.32	N/A

iBio has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

In the previous week, Alpha Teknova had 1 more articles in the media than iBio. MarketBeat recorded 1 mentions for Alpha Teknova and 0 mentions for iBio. iBio's average media sentiment score of 0.00 equaled Alpha Teknova'saverage media sentiment score.

Company	Overall Sentiment
iBio	Neutral
Alpha Teknova	Neutral

Summary

iBio and Alpha Teknova tied by winning 8 of the 16 factors compared between the two stocks.

How does iBio compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Fate Therapeutics currently has a consensus target price of $5.13, suggesting a potential upside of 109.18%. iBio has a consensus target price of $5.00, suggesting a potential upside of 257.14%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

iBio has lower revenue, but higher earnings than Fate Therapeutics. iBio is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	42.94	-$136.32M	-$1.09	N/A
iBio	$400K	173.88	-$18.38M	-$0.58	N/A

Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, iBio has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, Fate Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 1 mentions for Fate Therapeutics and 0 mentions for iBio. Fate Therapeutics' average media sentiment score of 1.04 beat iBio's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Fate Therapeutics	Positive
iBio	Neutral

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

iBio has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. iBio's return on equity of -53.86% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
iBio	N/A	-53.86%	-46.48%

Summary

iBio beats Fate Therapeutics on 9 of the 17 factors compared between the two stocks.

How does iBio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

iBio's return on equity of -53.86% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
iBio	N/A	-53.86%	-46.48%

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

iBio has higher revenue and earnings than ALX Oncology. iBio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
iBio	$400K	173.88	-$18.38M	-$0.58	N/A

ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, iBio has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, ALX Oncology had 3 more articles in the media than iBio. MarketBeat recorded 3 mentions for ALX Oncology and 0 mentions for iBio. ALX Oncology's average media sentiment score of 1.77 beat iBio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
ALX Oncology	Very Positive
iBio	Neutral

ALX Oncology presently has a consensus price target of $4.60, suggesting a potential upside of 137.11%. iBio has a consensus price target of $5.00, suggesting a potential upside of 257.14%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

iBio beats ALX Oncology on 9 of the 15 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.55M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.41	7.38	282.30	24.66
Price / Sales	173.88	1,201.52	564.98	76.51
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.56	16.78	10.92	6.07
Net Income	-$18.38M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-3.45%	-1.79%	-0.64%	-0.44%
1 Month Performance	-16.67%	-8.41%	-5.24%	-4.81%
1 Year Performance	N/A	48.37%	61.98%	18.61%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	1.8458 of 5 stars	$1.40 flat	$5.00 +257.1%	N/A	$69.55M	$400K	N/A	100
BCYC Bicycle Therapeutics	2.3447 of 5 stars	$3.86 -2.0%	$14.00 +262.7%	-51.7%	$275.06M	$72.86M	N/A	240	Earnings Report Upcoming Earnings Gap Up
IMRX Immuneering	2.5861 of 5 stars	$4.05 -4.5%	$17.57 +333.9%	+22.6%	$274.32M	N/A	N/A	60
TKNO Alpha Teknova	0.1267 of 5 stars	$4.96 -2.6%	N/A	+17.9%	$272.89M	$40.52M	N/A	240	Upcoming Earnings
FATE Fate Therapeutics	3.4093 of 5 stars	$2.36 +1.7%	$5.13 +117.2%	+129.0%	$270.42M	$6.65M	N/A	550	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. BCYC, IMRX, TKNO, FATE, and ALXO

How does iBio compare to Bicycle Therapeutics?

Summary

How does iBio compare to Immuneering?

Summary

How does iBio compare to Alpha Teknova?

Summary

How does iBio compare to Fate Therapeutics?

Summary

How does iBio compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. BCYC, IMRX, TKNO, FATE, and ALXO

How does iBio compare to Bicycle Therapeutics?

Which has stronger earnings and valuation, IBIO or BCYC?

Which has more risk and volatility, IBIO or BCYC?

Do insiders & institutionals hold more shares of IBIO or BCYC?

Do analysts rate IBIO or BCYC?

Does the media favor IBIO or BCYC?

Is IBIO or BCYC more profitable?

Summary

How does iBio compare to Immuneering?

Which has higher earnings & valuation, IBIO or IMRX?

Which has more volatility & risk, IBIO or IMRX?

Does the media refer more to IBIO or IMRX?

Do insiders & institutionals hold more shares of IBIO or IMRX?

Is IBIO or IMRX more profitable?

Do analysts rate IBIO or IMRX?

Summary

How does iBio compare to Alpha Teknova?

Do insiders and institutionals have more ownership in IBIO or TKNO?

Is IBIO or TKNO more profitable?

Do analysts prefer IBIO or TKNO?

Which has preferable earnings and valuation, IBIO or TKNO?

Which has more volatility & risk, IBIO or TKNO?

Does the media favor IBIO or TKNO?

Summary

How does iBio compare to Fate Therapeutics?

Do analysts recommend FATE or IBIO?

Which has stronger valuation & earnings, FATE or IBIO?

Which has more risk & volatility, FATE or IBIO?

Does the media prefer FATE or IBIO?

Do insiders & institutionals have more ownership in FATE or IBIO?

Is FATE or IBIO more profitable?

Summary

How does iBio compare to ALX Oncology?

Is ALXO or IBIO more profitable?

Do insiders and institutionals have more ownership in ALXO or IBIO?

Which has better earnings and valuation, ALXO or IBIO?

Which has more risk and volatility, ALXO or IBIO?

Does the media prefer ALXO or IBIO?

Do analysts recommend ALXO or IBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools